Zinaf-500 - Resultados de la búsqueda

tebrazid tablet

bausch health, canada inc. - pyrazinamide - tablet - 500mg - pyrazinamide 500mg - antituberculosis agents

Malta - inglés - Malta Medicines Authority

pyrazinamid tablets 500mg

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - pyrazinamide - tablet - pyrazinamide 500 mg - antimycobacterials

Estados Unidos - inglés - NLM (National Library of Medicine)

rifampin- rifampin capsule

a-s medication solutions - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - rifampin 300 mg - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (eg, rifater® 1) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tuberculosis, the a

Estados Unidos - inglés - NLM (National Library of Medicine)

rifampin- rifampin capsule

a-s medication solutions - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., rifater® 1) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tuberculosis, the